AMENDMENT IN THE NATURE OF A SUBSTITUTE TO H.R. 3887

Offered by M_..

Strike all after the enacting clause and insert the following:

1	SECTION 1. SHORT TITLE.
2	This Act may be cited as the "Children's Hospital
3	GME Support Reauthorization Act of 2023".
4	SEC. 2. PROGRAM OF PAYMENTS TO CHILDREN'S HOS-
5	PITALS THAT OPERATE GRADUATE MEDICAL
6	EDUCATION PROGRAMS.
7	Section 340E of the Public Health Service Act (42
8	U.S.C. 256e) is amended—
9	(1) in subsection (a), by striking "2023" and
10	inserting "2028";
11	(2) in subsection (b)(3)(D), by inserting "and
12	the end of fiscal year 2028," after "fiscal year
13	2022,";
14	(3) in subsection (e), by adding at the end the
15	following new paragraph:
16	"(4) Prohibition on payments to hos-
17	PITALS FURNISHING SPECIFIED PROCEDURES AND
18	DRUGS TO MINORS.—

1	"(A) IN GENERAL.—Notwithstanding any
2	other provision of this section, no payment may
3	be made under this section to a children's hos-
4	pital for a fiscal year (beginning with fiscal year
5	2024) if, at any point during the preceding fis-
6	cal year, such hospital furnished specified pro-
7	cedures and drugs (as defined in subsection (g))
8	to an individual under 18 years of age.
9	"(B) Special rule for fiscal year
10	2024.—In applying subparagraph (A) with re-
11	spect to payments described in such subpara-
12	graph for fiscal year 2024—
13	"(i) the reference to 'for a fiscal year'
14	shall be treated as a reference to 'for any
15	portion of fiscal year 2024 occurring after
16	December 31, 2023'; and
17	"(ii) the reference to 'the preceding
18	fiscal year' shall be treated as a reference
19	to 'the period beginning on September 1,
20	2023, and ending on December 31, 2023'.
21	"(C) Rule of Construction.—Nothing
22	in this paragraph shall be construed as prohib-
23	iting payments for a fiscal year (or, in the case
24	of payments for fiscal year 2024, during the
25	portion of such fiscal year described in subpara-

1	graph (B)(i)) to a hospital that, during the pre-
2	ceding fiscal year (or, in the case of payments
3	for fiscal year 2024, during the period de-
4	scribed in subparagraph (B)(ii)), furnished
5	mental or behavioral health services to individ-
6	uals under 18 years of age for the treatment of
7	gender dysphoria not consisting of specified
8	procedures and drugs.";
9	(4) in subsection (f)—
10	(A) in paragraph (1)(A)—
11	(i) in clause (v), by striking "and" at
12	the end;
13	(ii) in clause (vi), by striking the pe-
14	riod at the end and inserting "; and"; and
15	(iii) by adding at the end the fol-
16	lowing:
17	"(vii) for each of fiscal years 2024
18	through 2028, \$124,000,000."; and
19	(B) in paragraph (2)—
20	(i) in subparagraph (E), by striking
21	"and" at the end;
22	(ii) in subparagraph (F), by striking
23	the period at the end and inserting ";
24	and"; and

1	(iii) by adding at the end the fol-
2	lowing:
3	"(G) for each of fiscal years 2024 through
4	2028, \$261,000,000"; and
5	(5) in subsection (g), by adding at the end the
6	following new paragraph:
7	"(4) Specified procedures and drugs.—
8	"(A) In general.—Except as provided in
9	subparagraph (B), the term 'specified proce-
10	dures and drugs' means, with respect to an in-
11	dividual, any of the following:
12	"(i) Performing any surgery for the
13	purpose of changing the body of such indi-
14	vidual to correspond to a sex that differs
15	from their biological sex, including—
16	"(I) eastration;
17	$``(\Pi)$ orchiectomy;
18	"(III) scrotoplasty;
19	"(IV) vasectomy;
20	"(V) hysterectomy;
21	"(VI) oophorectomy;
22	"(VII) ovariectomy;
23	"(VIII) metoidioplasty;
24	"(IX) penectomy;
25	"(X) phalloplasty;

1	"(XI) vaginoplasty;
2	"(XII) vaginectomy;
3	"(XIII) vulvoplasty;
4	"(XIV) reduction
5	thyrochondroplasty;
6	"(XV) chondrolaryngoplasty; and
7	"(XVI) mastectomy.
8	"(ii) Any plastic surgery that femi-
9	nizes or masculinizes the facial features for
10	the purposes described in clause (i).
11	"(iii) Any placement of chest implants
12	to create feminine breasts for the purposes
13	described in clause (i).
14	"(iv) Any placement of fat or artificial
15	implants in the gluteal region for the pur-
16	poses described in clause (i).
17	"(v) Administering, supplying, pre-
18	scribing, dispensing, distributing, or other-
19	wise conveying to an individual medications
20	for the purposes described in clause (i), in-
21	eluding—
22	"(I) gonadotropin-releasing hor-
23	mone (GnRH) analogues or other pu-
24	berty-blocking drugs to stop or delay
25	normal puberty;

1	(Π) testosterone or other
2	androgens to biological females at
3	doses that are supraphysiologic to the
4	female sex; and
5	"(III) estrogen to biological
6	males at doses that are
7	supraphysiologic to the male sex.
8	"(B) Exception.—Subparagraph (A)
9	shall not apply to the following individuals:
10	"(i) An individual with both ovarian
11	and testicular tissue.
12	"(ii) An individual with respect to
13	whom a physician has determined through
14	genetic or biochemical testing that the in-
15	dividual does not have normal sex chro-
16	mosome structure, sex steroid hormone
17	production, or sex steroid hormone action.
18	"(iii) An individual experiencing infec-
19	tion, disease, injury, or disorder caused or
20	exacerbated by previous medical proce-
21	dures as defined in subsection $(g)(4)(A)$.
22	"(iv) An individual suffering from a
23	physical disorder, physical injury, or phys-
24	ical illness that would, as certified by a
25	physician, place the individual in imminent

1	danger of death or impairment of a major
2	bodily function unless the procedure is per-
3	formed.
4	"(C) BIOLOGICAL SEX.—For purposes of
5	subparagraph (A), the term 'biological sex'
6	means the indication of male or female sex by
7	reproductive potential or capacity, sex chro-
8	mosomes, naturally occurring sex hormones, go-
9	nads, or internal or external genitalia present at
10	birth.".

